Business
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live,
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com\nKing of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th, 2026. Mr. Bitterman will provide an overview of the Company's INTASYL siRNA platform and discuss recent clinical progress and priorities, followed by a live Q&A.\n\"We look forward to sharing why we believe INTASYL represents a differentiated approach to immuno-oncology and discussing our strategy for PH-762 as we plan for the next stage of development,\" said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.\nDATE: March 12th\nTIME: 11:00 AM ET\nREGISTER HERE\nAvailable for 1x1 meetings: March 16th & 17th. Schedule 1x1 Meetings here.\nThe event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.\nIt is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.\nLearn more about the event at www.virtualinvestorconferences.com.\nRecent Company Highlights\nPhio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.\nPhio has indicated that FDA engagement regarding next-st...